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Summary
Striking homology between signaling molecules in zebrafish and humans suggests that compounds known to inhibit human
kinases may enable a chemical genetic approach to dissect signaling pathways in the zebrafish embryo. We tested this
hypothesis using a vascular endothelial growth factor receptor inhibitor, PTK787/ZK222584. Zebrafish embryos treated
with this compound lacked all major blood vessels. Overexpression of AKT/PKB, a putative effector of vascular endothelial
growth factor signaling, allowed blood vessels to form in the presence of drug. Endothelial cell apoptosis induced by the
drug is prevented by increasing AKT/PKB activity, thus establishing the physiological relevance of AKT/PKB in the angio-
genic process. This approach allowed us to examine the effects of blood flow and the role of endothelial signals in
organogenesis.
Introduction ent zebrafish embryo permits easy visual analysis of phenotypic
defects. Currently, the simplest method for generating a loss-
of-function in a particular gene in the zebrafish is the use ofOur current knowledge on the physiological function of various
genes has benefited from studies using model organisms. Al- antisense technology using morpholino oligonucleotides to in-
duce a translational block in gene function (Nasevicius andthough informative, targeted gene disruption in mice blocks
function at such an early stage that it sometimes hinders the Ekker, 2000; Ekker, 2000). Although important information can
be obtained by morpholino injections, this method, similar toability to learn about gene function at later stages of develop-
ment. While conditional loss-of-function experiments are possi- the use of null mutations, blocks gene function at the earliest
stage. We set out to use a novel strategy to study signal trans-ble in the mouse (reviewed in Lewandoski, 2001; Mills, 2001),
these technologies do not allow much flexibility in and control duction in the zebrafish embryo using a chemical genetic ap-
proach to achieve a rheostatic control of signal strength. Weover residual gene function. In other model organisms, such as
Drosophila and C. elegans, the use of a controlled modulation used this strategy to study angiogenic signaling in the transpar-
ent zebrafish embryo.of gene dosage by temperature-sensitive and partial loss-of-
function alleles has generated valuable information on signaling The need for new blood vessels is important during em-
bryogenesis, as well as in pathological situations such as tumorpathways (reviewed in Rubin, 1991; Simon et al., 1991; Stern-
berg, 1993; Sternberg and Horvitz, 1991). However, inverte- growth (reviewed in Carmeliet and Jain, 2000). Thus, the molec-
ular dissection of angiogenic signaling is clinically relevant. Thebrates do not possess the extensive circulatory and other organ
systems of vertebrates, making them less than ideal for the formation of blood vessels and evaluation of blood flow is ex-
tremely easy to score in the zebrafish embryo, making it anstudy of more complex processes such as angiogenesis and
organ development. ideal model for the study of angiogenesis. The major regulators
of angiogenic signaling, the vascular endothelial growth factorsThe zebrafish provides an alternative vertebrate model sys-
tem. The fish possesses a complex circulatory system similar (VEGFs) and their receptors (VEGFRs), promote endothelial cell
differentiation, survival, and migration (reviewed in Carmeliet,to that of mammals, as well as reasonable counterparts for
many, although not all, of the other mammalian organ systems 2000; Ferrara and Alitalo, 1999). By addition of a kinase inhibitor
targeted against the VEGF receptors to the media bathing the(Kimmel et al., 1995; Isogai et al., 2001; Fishman, 2001; Thisse
and Zon, 2002). The rapid external development of the transpar- fish embryo, we phenocopied the loss of VEGF ligand function
S I G N I F I C A N C E
Our work represents a novel strategy to study signal transduction using a chemical genetic approach in an intact vertebrate organism.
The use of a chemical compound to dissect angiogenic signaling has allowed fine tuning of effective gene dosage. As in other
genetic models, such as Drosophila, we were able to bypass the receptor blockade by upregulating the activity of a putative
downstream effector, AKT/PKB. The combination of chemical genetics and the transparent zebrafish embryo can be used to study
other signal transduction pathways as well as for drug evaluation. The assays we have employed here are both inexpensive and
facile relative to mouse studies, suggesting that the zebrafish may be used as a preclinical model for drug testing.
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brought about by morpholino injections, where blood vessel
formation was prevented (Nasevicius et al., 2000). The chemi-
cally induced VEGF receptor defect can be ameliorated by
upregulating the activity of a putative downstream effector, AKT/
PKB, allowing for normal endothelial cell functions in migration
and survival.
Results
Molecular rationale for using a VEGF receptor
inhibitor in zebrafish
Preliminary to drug testing, we cloned and sequenced the full-
length zebrafish cDNAs for VEGFR-2/flk-1/KDR as well as for
several key members of its downstream signaling apparatus,
including PI3-kinase (p110 and p85), PTEN, and AKT-2/
PKB, and found high overall homology to their human counter-
parts (Figure 1 and J.C. and T.M.R., unpublished data). The
zebrafish VEGFR-2/flk-1/KDR cDNA is the full-length version of
the partial cDNAs previously reported by several other groups
(Fouquet et al., 1997; Liao et al., 1997; Sumoy et al., 1997;
Thompson et al., 1998). The high level of conservation in the
tyrosine kinase domain between human and zebrafish VEGFR-2
(78% identity, Figure 1A) provided a structural basis for use of
the antiangiogenic compound PTK787/ZK222584 on zebrafish
embryos.
Specific angiogenic inhibition by PTK787/ZK222584
phenocopies functional loss of VEGF-A ligand
PTK787/ZK222584 is a novel anilinophthalazine compound and
a high affinity inhibitor of the VEGF receptors, with a higher
potency toward VEGFR-2/KDR than VEGFR-1/Flt-1 (IC50  37
nM and 77 nM, respectively; Wood et al., 2000). Although it
also exhibits inhibitory activity toward the PDGF, Flt-4, and c-Kit
receptors, this occurs at higher concentrations (Wood et al.,
2000; Bold et al., 2000). Previous studies have shown the effec-
Figure 1. Molecular basis for chemical inhibition and VEGF pathway conser-tiveness of this drug in cell culture and in murine retina neovas-
vation
cularization and carcinoma models (Wood et al., 2000; Bold et
A: Sequence comparison of the predicted protein-tyrosine kinase domain,
al., 2000; Drevs et al., 2000; Ozaki et al., 2000). We first tested residues 808 to 1134 of zebrafish (top) with human (bottom) VEGFR-2. Hall-
the effectiveness of this compound on the zebrafish VEGFR-2 mark residues of kinase subdomains I, II, VI, VII, and VIII are indicated by
red letters. B: Expression and chemical inhibition of the zebrafish VEGFR-2receptor expressed in vitro in mammalian cells, where ligand-
receptor by PTK787/ZK222584 in mammalian cells. Lane 1, vector-trans-induced autophosphorylation of the zebrafish receptor was in-
fected COS cell lysates; lanes 2–4, zebrafish VEGFR-2-transfected COS cell
hibited by PTK787/ZK222584 at approximately the same con- lysates. COS cells in lanes 1, 2, and 3 were stimulated with zebrafish VEGF-A
centrations used on the mammalian VEGF receptors (Figure ligand. Cells in lane 3 were preincubated with 100 nM PTK787/ZK222584 for
receptor inhibition. Cells in lane 4 express the zebrafish VEGFR-2 receptor.1B). Treatment of live fish embryos with PTK787/ZK222584
Cell lysates were immunoprecipitated with anti-phosphotyrosine antibodycompletely blocked the formation of all major blood vessels at
and immunoblotted with the same antibody to show a tyrosine phosphory-
a concentration of 5 M in fish embryo media (Figure 2 and lated band of the expected size for the zebrafish VEGFR-2 receptor, 180
Table 1). At 1 M, we observed a 34% vessel inhibition in our to 200 kDa. C: Sequence alignment of predicted zebrafish (top) and human
(bottom) AKT-2 protein. The PH domain is indicated by a red overline; thesystem (Table 1), which may be compared to its use at plasma
protein-serine/threonine kinase domain is indicated by blue arrows. Theconcentrations above 1 M in mouse tumor studies (Wood et
residues boxed in red correspond to Thr308 and Ser473 phosphorylation
al., 2000; Drevs et al., 2000; Ozaki et al., 2000). The PTK787/ sites of human AKT-1. For both A and B, identical residues are boxed in blue,
ZK222584-induced antiangiogenic phenotype is remarkably similar residues in gray. The full-length cDNAs encoding zebrafish VEGFR-2
and AKT-2 have been submitted to GenBank: VEGFR-2/flk (accession num-similar to the loss of VEGF-A ligand function produced by anti-
ber AY056466), AKT-2 (accession number AY056465); human sequencessense morpholino targeting (Figures 2A–2D; Nasevicius et al.,
were taken from GenBank.
2000). Embryos treated with PTK787/ZK222584 showed a com-
plete blockade of blood vessel formation as the dorsal artery
and posterior cardinal vein fail to form by 48 hr of development
(Figures 2G–2J). This results in severe pericardial edema (Figure (Figures 2A and 2B) argues strongly for the selectivity of
2D), with further complications of heart failure and embryonic PTK787/ZK222584 for VEGF receptors. The potent antiangio-
death by 3 days of development. The lack of deleterious effects genic effect of PTK787/ZK222584 is further confirmed by a
significant reduction of endothelial cells in the region of theon the general morphology of embryonic structures by 24 hpf
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Figure 2. PTK787/ZK222584 treatment of live ze-
brafish embryos specifically inhibits angiogenesis
Zebrafish embryos were treated at shield stage
(60% epiboly, 6 hpf) with PTK787/ZK222584 (B, D,
F, H, J, L, N, and P, as indicated), and compared
with same stage untreated embryos (A, C, E, G,
I, K, M, and O, respectively). A–D: Lateral views
of live embryos at 24 hpf (A and B) and 48 hpf (C
and D). PTK787/ZK222584-treated embryos were
shorter in length, as indicated by red arrows; the
blue arrow in D indicates pericardial edema. E,
F, and I–P: In situ RNA hybridization with various
endothelial cell markers. VEGFR-2/flk-1 RNA stain-
ing of 24 hr embryos in E and F, 48 hr embryos
in I and J. G and H: Hematoxylin-eosin/azure II
staining of transverse sections of 48 hr embryos
revealing the lumens of the dorsal artery, A, and
vein, V, in the control embryo (G); and their ab-
sence in the PTK787/ZK222584-treated embryo
(H). I and J: 48 hr embryos stained with the
VEGFR-2/flk-1 RNA probe, and flat-mounted at
the level of the dorsal artery and posterior
cardinal vein to show the absence of VEGFR-2/
flk-1-positive endothelial cells in the drug-treated
embryo (J). K and L: 36 hr embryos stained with
the early endothelial marker fli-1. M and N: 30 hr
embryos stained with the ephrinB2a marker for
arterial endothelial cells. O and P: 36 hr embryos
stained with the venous endothelial marker flt4.
Endothelial cell staining is reduced or absent
from all PTK787/ZK222584-treated embryos (J, L,
N, and P). Abbreviations: PTK787, PTK787/
ZK222584 treatment; NT, neural tube; noto, noto-
chord; A, dorsal artery; V, posterior cardinal vein.
Scale bars for A–D  500 m; E and F  500 m;
G and H  50 m; I and J  100 m; K–P 
100 m.
dorsal artery and posterior cardinal vein at 24 hpf, and by their fish, a strict requirement for blood flow determines proper glo-
merular assembly (Serluca et al., 2002). The lack of aortic bloodabsence at 48 hpf as indicated by flk-1/VEGFR-2 in situ RNA
staining (Figures 2E, 2F, 2I, and 2J). This is confirmed by the flow in embryos treated at early stages with PTK787/ZK222584
generated defects in glomerulogenesis, as wt1-positive cellsdistinctive absence of these major blood vessels by 48 hpf when
viewed in transverse section (Figures 2G and 2H). We analyzed remain unmerged at 48 hpf and beyond (Figures 3D–3F). How-
ever, later administration of drug, after the onset of aortic flowthis defect further using established endothelial markers: fli1 for
endothelial precursors (Figures 2K and 2L; Thompson et al., by 26 hpf, allowed for glomerular assembly, demonstrating that
PTK787/ZK222584 does not illicit a deleterious effect on kidney1998) and ephrin B2a for arterial endothelial cells (Figures 2M
and 2N; Chan et al., 2001), as well as flt4 for venous endothelial development on its own (Figure 3C). We also examined the
development of the endocrine pancreas (insulin; Figures 3G andcells (Figures 2O and 2P; Thompson et al., 1998). In all cases,
endothelial cell staining was either abolished or significantly 3H; Milewski et al., 1998; Argenton et al., 1999), the exocrine
pancreas (trypsin, Figures 3I and 3J; Biemar et al., 2001) as wellreduced in the region of the major dorsal vessels in the PTK787/
ZK222584-treated animal, as compared with same stage con- as the liver (fkd2; Figures 3K and 3L; Chen et al., 2001) using
established in situ markers. In spite of the dramatic reductiontrols (Figures 2I–2P).
Since early administration of PTK787/ZK222584 resulted in of endothelial cells (Figures 2E–2P), all markers are expressed
(Figures 3G–3L). However, the expression domains for trypsinzebrafish embryos that do not possess an intact dorsal artery
or vein and have no aortic blood flow, it prompted us to examine and fkd2 appear shortened along the anterior-posterior axis
(Figures 3I–3L).organogenesis in treated animals (Serluca et al., 2002; Lammert
et al., 2001; Matsumoto et al., 2001). During kidney formation,
intermediate mesoderm precursor cells expressing the Wilms’ Use of chemical genetics allows precise temporal and
dosage control of receptor inhibitiontumor suppressor gene (wt1) migrate toward the midline and
coalesce around a vascular sprout from the aorta to form the Unlike antisense targeting strategies, this antiangiogenic com-
pound can be administered at any stage of development toglomerulus (Serluca and Fishman, 2001). These cells mark the
bilateral pronephric primordia by 36 hpf (Figure 3A) that develop block the formation of particular blood vessels as they develop
during the first few days of embryonic and larval life (data notinto the midline glomerulus by 48 hpf (Figure 3B). In the zebra-
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Overexpression of the downstream effector AKT/PKBTable 1. Analysis of angiogenic phenotypes in live zebrafish embryos
can rescue VEGF receptor blockadeAntiangiogenic effects of PTK787/ZK222584 at various
In Drosophila genetics it has been possible to tentatively estab-concentrationsa
lish the order of signaling molecules in a pathway by rescuing
PTK787 Dorsal artery Dorsal artery
a partial loss of function mutation in one component by upregu-concentration absent present Number
lating the activity of a downstream component. Recent evidence
10 M 100% 0% 200 suggests a role for PI 3-kinase and PTEN in angiogenic signaling5 M 100% 0% 200
(Jiang et al., 2000; Wen et al., 2001). In particular, cell culture2.5 M 81% 19% 220
1 M 34% 66% 200 studies have suggested a role for AKT/PKB as a downstream
0.5 M 6% 94% 200 effector of VEGF signaling (Gerber et al., 1998; Fujio and Walsh,
0.25 M 0% 100% 200 1999). In addition to the optical transparency of the embryo, the
Antiangiogenic effects of 10 M PTK787/ZK222584b at various stages zebrafish is also amenable to mRNA microinjection experiments,
which permit exogenous expression of activated forms of intra-Embryo stage Mild Moderate Severe
at treatment defectc defectd defecte Death Number cellular proteins. We tested whether overexpression of AKT/
PKB, a putative downstream element, could rescue drug-1-cell to 18S 0% 0% 90% 10% 200
induced loss of receptor function by microinjecting embryos at24 hpf 0% 0% 95% 5% 200
30 hpf 26% 25% 49% 0% 200 the one-cell stage with myristoylated-AKT/PKB mRNA prior to
36 hpf 78% 17% 5% 0% 200 PTK787/ZK222584 treatment. As the conservation in the PI
AKT-mediated blood vessel recovery upon VEGF receptor or ligand 3-kinase pathway between fish and man is generally high (Figure
inhibition 1C; Chan and Roberts, in preparation), we decided to use a
constitutively activated version of human AKT-1/PKB (Rama-Good Moderate Poor
Experimental conditions recoveryc recoveryd recoverye Number swamy et al., 1999) in our analysis. We observed much faster
and more efficient recovery of intersegmental vessels in drugPTK787 treatment and washoutf
Uninjected embryos 8% 25% 67% 200 washout experiments in embryos overexpressing activated
AKT injected embryos 37% 29% 34% 200 AKT/PKB as compared with uninjected controls (Figures 4C
GFP injected embryos 6% 32% 62% 200 and 4D, Table 1), while a kinase-dead version of myristoylated-
No treatment 100% 0% 0% 200
AKT/PKB was unable to override the receptor defect (Figure
VEGF morpholino injectionsg 5). We also tested the ability of another potential downstream
VEGF morpholino 0% 19% 81% 200 effector, endothelial nitric oxide synthase (eNOS), which is pref-VEGF morpholino  AKT 12% 41% 47% 200
erentially expressed in endothelial cells and known to participate
a Embryos were treated at 60% epiboly and staged according to Kimmel in VEGF receptor signaling in cultured cells. Phosphorylation of
et al. (1995).
bovine eNOS by AKT/PKB at Ser1179 (Ser1177 in human eNOS)b Observations were recorded at 48 hpf.
has been shown to upregulate its activity (Fulton et al., 1999;c Intersegmental vessels at 50% the normal number.
d Intersegmental vessels at 30–50% the normal number. Dimmeler et al., 1999). Using mRNA encoding either an acti-
e Intersegmental vessels at 30% the normal number. vated form of eNOS (S1179D, which mimics the AKT/PKB phos-
f Embryos were treated at 24 hpf, with 10 M of PTK787/ZK222584. Drug was phorylation) or an AKT/PKB-resistant version, S1179A, in drugwashed out at 30 hpf and embryos were examined at 48 hpf.
washout experiments, we observed a modest rescue in theg Embryos were injected with either VEGFA3 morpholino alone or in combi-
nation with myrAKT mRNA at the one-cell stage and examined at 52 hpf. number of intersegmental vessels with the activated version of
Abbreviations: PTK787, PTK787/ZK222584; 18S, 18-somites; hpf, hours postfer- eNOS. The rescue was statistically significant but not as robust
tilization. as that seen with AKT/PKB (Figure 5 and Table 1).
Experiments in cultured endothelial cells suggest that the
overexpressed AKT/PKB could be acting, at least in part, by
preventing endothelial cell apoptosis (Gerber et al., 1998; Fujio
and Walsh, 1999), but we wondered if our mRNA injectionsshown). From 24 hpf to 48 hpf, the development of the interseg-
were having more global effects on cell survival. To investigatemental vessels in the zebrafish can be easily visualized using
this, we determined the extent of apoptosis in whole-mountlive embryo microangiography (Weinstein et al., 1995; Isogai et
TUNEL assays (Figure 6). In control embryos, we observed theal., 2001), where a fluorescent dye is injected into the embryonic
naturally occurring apoptosis in the neural tube at 48 hpf (Figurescirculation (Figure 4). When embryos are treated with PTK787/
6A and 6B). When embryos are treated with drug after theZK222584 after the establishment of blood flow in the dorsal
establishment of blood flow by 24 hpf, the amount of apoptotic
artery and cardinal vein at 24 hpf, the intersegmental vessels
cell death in the region of the dorsal artery and vein is dramati-
fail to form (Table 1). cally increased (Figures 6C and 6D). In contrast, when embryos
Since PTK787/ZK222584 is a reversible competitor, we per- overexpressing activated AKT/PKB are exposed to the same
formed drug washout experiments where embryos were treated drug treatment, the amount of apoptotic cell death is reduced
with the compound from 24 hpf to 30 hpf, after which the drug to background levels in the region of the blood vessels (Figures
was removed by serial washes in embryo media before an incu- 6E and 6F). However, exogenous AKT/PKB activity did not ap-
bation period in drug-free embryo media (Figure 4C and Table pear to have a protective effect on the normal apoptosis in the
1). We observed that after drug removal, some intersegmental neural tube. The specificity of PTK787/ZK222584 effects on
vessels are formed. However, these rescued vessels are mark- endothelial cells is underscored by comparison with wortmannin
edly fewer in number as compared with same-stage control treatment of live embryos, where a high level of apoptotic cell
death was observed throughout the embryo (Figures 6G and 6H).embryos (Figures 4B and 4C).
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Figure 3. Organogenesis in PTK787/ZK222584-
treated zebrafish embryos
Antisense RNA staining of whole-mount embryos,
dorsal views with anterior to the left in all panels.
A–F: Kidney glomerular assembly was examined
using the wt1 probe. Control embryos at 36 hr
(A) and 48 hr (B) stained with wt1 show the migra-
tion of the bilateral podocytes (red arrows) to-
ward the midline where fusion occurs by 48 hpf
as indicated by the green arrow. When embryos
are treated with PTK787/ZK222584 at shield stage
(60% epiboly, 6 hpf) before aortic blood flow, the
wt1-positive cells do not fuse at the midline (D,
E, and F). PTK787/ZK222584-treatment after aortic
flow at 26 hpf in C. Migration of wt1-positive
podocytes toward the midline appears unaf-
fected. G–L: insulin, trypsin, and fkd2 staining of
control (G, I, and K) and PTK787/ZK222584-
treated (H, J, and L) embryos, showing the loca-
tions of the endocrine pancreas, the exocrine
pancreas, and the liver, respectively. Abbrevia-
tions: PTK787, PTK787/ZK222584 treatment. Scale
bar for all panels indicates 200 m.
Inhibitors of serine/threonine kinases can phenocopy likely secondary to the gross deformity in the trunk (Figures 7E
and 7F).known defects
To see if the zebrafish could be used to study both tyrosine
Discussionand serine/threonine kinase inhibitors, we also tested the effec-
tiveness of a broad spectrum protein kinase C inhibitor, PKC412
The use of an inhibitor in place of the classic loss-of-function(Meyer et al., 1989), and an inhibitor of MEK, U0126 (Favata et
mutation allows us to perform experiments which would beal., 1998). Treatment of zebrafish embryos with PKC412 gener-
extremely difficult or impossible in the fish using either mutationsated a distinctive curvature of the body axis which phenocopies
in the VEGF receptors or downregulation via antisense or RNAthat of the genetic zebrafish mutant, heart and soul (has) (Stainier
interference technology. During the development of the verte-et al., 1996; Figures 7A–7D). Recent work has shown that the
brate organism, the exact timing of developmental events ishas mutant harbors stop codons in the coding region of an
crucial to the formation of tissues and organ systems. A chemi-atypical protein kinase C gene, PKC (Peterson et al., 2001;
cal genetic approach permits both temporal and dosage controlHorne-Badovinac et al., 2001). Treatment of fish embryos with
over the modulation of gene function, allowing precise initiationa Mek inhibitor, U0126, induced a specific loss of posterior
and termination of the functional blockade (Peterson et al., 2000,
structures which phenocopies the published effects of expres-
2001). Controlled administration of PTK787/ZK222584 inacti-
sion of a dominant-negative Raf in the Xenopus (Figures 7E and vated VEGF receptors at the most important time in the angio-
7F; MacNicol et al., 1993). To examine the effects of these genic process. In addition, the drug also allows us to block
compounds on zebrafish angiogenesis, we performed in situ multiple receptor alleles in one facile step.
RNA staining with the endothelial marker flk-1 (Figures 7G–7J). To study signaling components in this pathway, we bor-
At 24 hpf, PKC412-treatment did not significantly reduce endo- rowed an idea from Drosophila studies where genetic rescue
thelial cell staining as compared with control or has embryos of a hypomorphic allele is commonly used in pathway mapping
(Figures 7G–7I). Thus, PKC412 did not generate antiangiogenic (Simon et al., 1991). We reasoned that when the VEGF receptor
effects as PTK787/ZK222584 when used on live zebrafish em- was impaired, a low level activity of a downstream component
bryos in the same treatment regime (Figures 7G–7I; Figure 2). might provide just enough pathway activation to achieve the
Similar examination of U0126 effects showed that endothelial signaling threshold necessary for endothelial cell function. Previ-
cells are present but their expression domain is deformed (Fig- ous work in cultured endothelial cells has shown that the AKT/
PKB branch of PI 3-kinase signaling is essential for VEGF-medi-ure 7J). The morphological changes in flk-1-positive cells are
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Figure 4. Microangiography of live zebrafish embryos following PTK787/
ZK222584-treatment and drug washout experiments
Figure 5. Comparison of AKT/PKB versus eNOS in vessel rescueLive zebrafish embryos at 2 days of development were injected with a
fluorescent lectin dye and circulation was visualized using an epifluores- y axis indicates the mean number of intersegmental vessels per mRNA-
cence microscope. A: Microangiograph of the circulation in a control un- injected embryo in PTK787/ZK222584 washout experiments as described. x
treated embryo within minutes of dye injection into the pumping embryonic axis indicates various mRNAs injected: GFP for control; myrAKT for myristoy-
heart, indicated by the orange arrow. B–D: Higher magnification of the lated, activated AKT/PKB, myrAKT-KD for the kinase-dead version; eNOS
same stage embryos focusing on the intersegmental vessels along the trunk S1179D for activated and eNOS S1179A for AKT/PKB resistant versions of
of the embryo. The control embryo (B) shows a regular spacing of interseg- eNOS. n 	 200; p  0.0001 by one-way analysis of variance. Error bars
mental vessels. C and D: After the establishment of flow in the dorsal artery show the 95% confidence limits. Only myrAKT/PKB and eNOS S1179D show
and posterior cardinal vein at 24 hpf, embryos were treated with PTK787/ statistically significant differences (p  0.05) from GFP-injected fish, both at
ZK222584 for a period of 6 hr, the drug was washed out at 30 hr, and the p  0.0001 by two-tailed unpaired t test.
embryos were allowed to recover until 48 hpf before microangiography.
Note the reduced number of intersegmental vessels in C. Embryo in D was
injected with myristoylated-AKT/PKB mRNA at the one-cell stage before
drug treatment, and displayed more vessels. Abbreviations: PTK787, PTK787/
ZK222584 treatment; AKTPTK787, injected with AKT/PKB mRNA before higher levels, AKT/PKB overexpression generated gastrulation
PTK787/ZK222584 treatment; DA, dorsal artery; PCV, posterior cardinal vein; defects. Our rescue experiments with eNOS yielded a statisti-
ISV, intersegmental vessel. Scale bars for A  200 m; B–D  200 m. cally significant but very modest rescue (Figure 6 and Table 1).
Since AKT/PKB is upstream of eNOS in its signaling pathway
(Fulton et al., 1999; Dimmeler et al., 1999), it is perhaps not
surprising that AKT/PKB generates a more robust rescue.ated cell survival and migration (Gerber et al., 1998; Fujio and
Our study serves to illustrate the interdependence of signalWalsh, 1999; Morales-Ruiz et al., 2000). We tested the ability
transduction research and inhibitor drug action. There is a cer-of AKT/PKB to provide a functional bypass in receptor blockage
tain reciprocity in the information flow arising from studying theby looking at vessel recovery after a 6 hr exposure to PTK787/
interaction of potential drugs in zebrafish: the fish can give usZK222584. Judging by the number of intersomitic vessels
information about compounds under study, but the compoundsformed after washout, we determined that a low level of exoge-
can also reveal the mechanisms regulating development. Highlynous AKT/PKB activity generated a much more robust rescue
specific inhibitors can help us immensely in elucidating signalthan in uninjected controls (see Table 1). Thus, endothelial cell
transduction pathways, while the flaws of less specific com-function, in this case, as indicated by the ability to migrate into
pounds may be revealed by their effects on development.the intersomitic region and form functional vessels, is rescued
PTK787/ZK222584 is specific and hence has provided us valu-in the presence of increased AKT/PKB activity (Figure 4 and
able information about the VEGF receptor signaling pathway inTable 1). Since AKT/PKB is a molecule with ubiquitous expres-
angiogenesis and allowed us to examine the consequences ofsion and pleiotropic effects, we cannot rule out the possibility
receptor inhibition on organ development in an intact organism.that AKT/PKB is acting in a pathway independent from the VEGF
The absolute lack of blood flow that resulted from chemicalreceptor signaling pathway. However, our data is much more
inhibition at early stages prevented glomerulogenesis duringeasily explained by the simple hypothesis that rescue occurs
kidney formation as predicted from previous studies (Figuresfor VEGF signaling. Notably, upregulated AKT/PKB activity was
3A–3F; Serluca et al., 2002). The formation of the endocrineable to rescue the VEGF receptor defect created by the drug,
pancreas, as marked by insulin staining, does not appear differ-but not the naturally occurring apoptosis in the neural tube.
ent after drug treatment, suggesting that the lack of an intactSince, by design, the 6 hr pulse of drug in washout experiments
aortic endothelium and blood flow is insufficient to alter pancre-had been tailored to leave considerable residual VEGF receptor
atic development at this stage. In studies in mouse and Xenopus,function, we would expect that the levels of AKT/PKB activity
the development of the endocrine pancreas has been shownneeded to rescue drug action would not be sufficient to rescue
to depend on interactions with the endothelium (Lammert et al.,natural apoptosis. Unfortunately, we were not able to further
2001). It is possible that in the fish, endothelial interactions aretest this hypothesis by raising AKT/PKB activity still higher in
an attempt to rescue cell death in the neural tube, because at not required for pancreatic development, or alternatively there
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flh mutants, like our drug treated fish, still display limited num-
bers of endothelial cells (Fouquet et al., 1997), perhaps enough
for induction of the endocrine pancreas. As recent data sug-
gested a requirement for sonic hedgehog (shh) signaling in ze-
brafish pancreatic specification (Roy et al., 2001), we also con-
firmed that shh expression is not altered in our chemical
inhibitions (data not shown). Although the general staining and
morphological location of the endocrine and exocrine pancreas,
as well as the liver primordia, appear to be correct, the expres-
sion domains of two of these markers are reduced along the
anterior-posterior axis (Figures 3G–3L), suggesting that endo-
thelial signals may be required for organ morphogenesis without
affecting cellular differentiation. In the case of liver development,
our preliminary analysis is consistent with that of Matsumoto
et al. (2001) in flk-1/VEGFR-2 null mice, which showed that
specification of the liver does occur in the absence of vessels.
These data suggest that our system can be further developed to
explore developmental questions in organogenesis in an intact
animal without surgical manipulation. Since signals between
endothelial cells and developing tissues during organogenesis
may be reprised during tumor angiogenesis, understanding
these interactions may improve our understanding of cancer
biology.
In these proof of concept experiments, the drug target was
already known, but we feel that the system could be of value
in determining the mechanisms of action of novel compounds.
If PTK787/ZK222584 targets had been unknown, its potent anti-
angiogenic effects on the fish would have pointed to the correct
pathway if not to the exact target. Our rescue experiment sug-
gests that it may be possible to locate the target of a drug within
a pathway by overexpressing various pathway members. In the
course of this study, we have also tested serine/threonine kinase
inhibitors, PKC412 and U0126, for their ability to induce specific
phenotypes in the zebrafish. PKC412 generated a distinctive
curvature of the body axis which phenocopied that of the genetic
zebrafish mutant, heart and soul (has) (Stainier et al., 1996),
which resulted from mutations in the protein kinase C gene,
PKC (Peterson et al., 2001; Horne-Badovinac et al., 2001). InFigure 6. PTK787/ZK222584-induced endothelial cell apoptosis can be spe-
the case of MEK, drug inhibition phenocopies Raf-1 interferencecifically prevented with overexpression of activated AKT/PKB
in Xenopus embryos (MacNicol et al., 1993).Whole-mount TUNEL assays were performed on untreated and PTK787/
ZK222584-treated embryos. A, C, E, and G: Lateral views of flat-mounted Any study using small molecule inhibitors must address the
embryos; B, D, F and H: manual cross-sections of the same embryos, respec- issue of target specificity. For instance, PTK787/ZK222584 is
tively. A and B: Control untreated embryos showing endogenous apoptotic known to inhibit the platelet-derived growth factor (PDGF) and
cell death along the neural tube, red arrowhead in all panels. C–F: Embryos
the c-Kit receptors at higher concentrations (Bold et al., 2000;were treated with PTK787/ZK222584 at 24 hpf and fixed at 48 hpf for TUNEL
analysis. Exposure to PTK787/ZK222584 induced endothelial cell death at Wood et al., 2000). Inhibition of these receptors is unlikely to
the region of the dorsal artery and posterior cardinal vein (C and D); blue underlie our antiangiogenic phenotype since we would expect
arrows indicate position of endothelial cells in all panels. Embryos injected to see alterations in pigmentation if either receptor were being
at the one-cell stage with myristoylated-AKT/PKB showed reduced apo-
inhibited. Mutation of the c-kit gene in the zebrafish sparseptotic cell death in the endothelial cells, but apoptosis along the neural
mutant results in reduced melanocyte production (Parichy ettube appears unaffected in E and F. Embryos were treated with 5 M
wortmannin at 24 hpf and fixed at 48 hpf for TUNEL analysis in the same al., 1999). From the Patched mutation in mice, we also expect
manner in G and H. Scale bar for all panels indicates 50 m. that PDGF receptor inhibition would generate pigment defects
(Smith et al., 1991; Stephenson et al., 1991). To address these
concerns in a more general way, we used a VEGF ligand mor-
pholino (Nasevicius et al., 2000) to block the VEGF receptormay be a sufficient number of endothelial cells in drug treated
pathway. We were able to obtain a specific antiangiogenic phe-fish to allow pancreas formation. In the zebrafish, the notochord,
notype that could, with some difficulty, be rescued by coinjec-which is required for dorsal artery formation (Fouquet et al.,
tion with myristoylated AKT/PKB mRNA (Table 1). By lowering1997), does not appear to be a source of inductive signals in
the amount of VEGF-A morpholino injected, while adjusting thepancreatic development. The genetic mutant, floating head, flh,
amount of myristoylated AKT/PKB mRNA in the coinjection ex-which lacks a notochord, still exhibits normal insulin expression
in the proper morphological location (Biemar et al., 2001). The periment, we were able to generate more intersegmental vessels
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Figure 7. Serine/threonine kinase inhibitors can
phenocopy known in vivo defects
A–D: Zebrafish embryos treated with 100 nM
PKC412 at shield stage (6 hpf, A and B) gener-
ated a curved body axis similar to the genetic
mutant, heart-and-soul (has), at 24 hpf and 48
hpf (C and D). E and F: Embryos treated with 100
M of U0126 at shield stage (6 hpf) displayed a
loss of posterior structures. G–J: In situ RNA stain-
ing with an endothelial marker indicates the
presence of flk-1 positive cells in the control, has,
PKC412-treated, and U0126-treated embryos at
24 hpf. Scale bars for A–F  500 m; G–J 
100 m.
at 48 hpf, compared with embryos injected with the lowered cient and quick system for a prescreen. A single person can
generate thousands of animals and test numerous compoundsVEGF-A morpholino alone (Table 1).
on a daily basis. The rapid development of the transparentInevitably the system will fail to assess some compounds
zebrafish embryo permits easy visual analysis of phenotypiccorrectly. For instance the zebrafish homolog of the c-Kit recep-
defects. In addition, accumulating genetic data from zebrafishtor is well conserved, and yet STI571, a potent inhibitor of the
mutants will provide a growing database for phenotypic com-both c-Abl and c-Kit kinases, fails to phenocopy a genetic c-kit
parison of functional loss in a given signaling pathway.mutation (Parichy et al., 1999) or indeed have any effect on
zebrafish development (J.C. and T.M.R., unpublished data).
Experimental proceduresHowever, our experience to date suggests that the zebrafish
system will be useful in evaluating many signaling drugs. In Maintenance of zebrafish and drug treatments
particular, we suggest that the zebrafish system can play a Breeding fish were maintained at 28.5
C on a 14 hr light/10 hr dark cycle.
Embryos were collected by natural spawning, raised in 10% Hank’s saline,useful role as an initial animal screen before investment in more
and staged up to 24 hr (30 somites) according to Kimmel et al. (1995);costly and time-consuming rodent studies.
beyond this point, embryo stage is given as hours post fertilization (hpf).No model system is perfect, but the zebrafish system offers
Kinase inhibitors, PTK787/ZK222584, and PKC412 (Novartis Pharma AG,a unique combination of advantages that strengthen its potential Basel, Switzerland), were dissolved in DMSO at stock concentrations of 2
as a prescreen model for drug evaluation. It is inexpensive; at mM; U0126 (Promega) was dissolved at 50 mM in DMSO, then diluted in
less than 1% of the cost of maintaining mice, the number of embryo media (Westerfield, 1995) and added to live zebrafish embryos at
the stages indicated. Control embryos were treated with the equivalentembryos available for drug treatment can be much higher. As
amount of DMSO solution. All embryos are incubated at 28.5
C.the sample numbers increase, statistical confidence in the out-
come of the experiment improves. Equally importantly, the
Isolation and characterization of cDNA clones
amount of a compound required is small. In the course of this for VEGFR-2 and AKT/PKB-2
study we tested over 30,000 animals, with less than 5 mg of The cDNAs encoding rat EphA8 receptor tyrosine kinase domain (Chan and
Watt, 1991) and the human AKT-1/PKB- (Ramaswamy et al., 1999) werePTK787/ZK222584 for the entire study.
used to screen an 18 hr zebrafish embryonic cDNA library at low stringencyThe sequencing of the human genome has revealed an ex-
(Chan et al., 2001). Full-length cDNA clones were isolated encoding zebrafishtremely large number of potential targets for drug design. How-
VEGFR-2/flk-1/KDR receptor and AKT-2/PKB: VEGFR-2, AKT-2/PKB
ever, candidate drugs require extensive testing in model ani- (GenBank accession numbers: AY056466, AY056465, respectively). Nucleo-
mals. Current mammalian models are expensive to house and tide sequences were determined using the dideoxy method by the Dana-
Farber Cancer Institute Molecular Biology Core Facility.time-consuming to use. The zebrafish can provide a cost-effi-
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